Literature DB >> 24818658

Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.

Raffaele Capasso1, Pierangelo Orlando, Ester Pagano, Teresa Aveta, Lorena Buono, Francesca Borrelli, Vincenzo Di Marzo, Angelo A Izzo.   

Abstract

BACKGROUND AND
PURPOSE: Palmitoylethanolamide (PEA), a naturally occurring acylethanolamide chemically related to the endocannabinoid anandamide, interacts with targets that have been identified in peripheral nerves controlling gastrointestinal motility, such as cannabinoid CB1 and CB2 receptors, TRPV1 channels and PPARα. Here, we investigated the effect of PEA in a mouse model of functional accelerated transit which persists after the resolution of colonic inflammation (post-inflammatory irritable bowel syndrome). EXPERIMENTAL APPROACH: Intestinal inflammation was induced by intracolonic administration of oil of mustard (OM). Mice were tested for motility and biochemical and molecular biology changes 4 weeks later. PEA, oleoylethanolamide and endocannabinoid levels were measured by liquid chromatography-mass spectrometry and receptor and enzyme mRNA expression by qRT-PCR. KEY
RESULTS: OM induced transient colitis and a functional post-inflammatory increase in upper gastrointestinal transit, associated with increased intestinal anandamide (but not 2-arachidonoylglycerol, PEA or oleoylethanolamide) levels and down-regulation of mRNA for TRPV1 channels. Exogenous PEA inhibited the OM-induced increase in transit and tended to increase anandamide levels. Palmitic acid had a weaker effect on transit. Inhibition of transit by PEA was blocked by rimonabant (CB1 receptor antagonist), further increased by 5'-iodoresiniferatoxin (TRPV1 antagonist) and not significantly modified by the PPARα antagonist GW6471. CONCLUSIONS AND IMPLICATIONS: Intestinal endocannabinoids and TRPV1 channel were dysregulated in a functional model of accelerated transit exhibiting aspects of post-inflammatory irritable bowel syndrome. PEA counteracted the accelerated transit, the effect being mediated by CB1 receptors (possibly via increased anandamide levels) and modulated by TRPV1 channels.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24818658      PMCID: PMC4243976          DOI: 10.1111/bph.12759

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  66 in total

1.  A new model of visceral pain and referred hyperalgesia in the mouse.

Authors:  J M A Laird; L Martinez-Caro; E Garcia-Nicas; F Cervero
Journal:  Pain       Date:  2001-06       Impact factor: 6.961

Review 2.  Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system.

Authors:  Peter Holzer
Journal:  Pharmacol Ther       Date:  2011-03-21       Impact factor: 12.310

Review 3.  Peripheral mechanisms in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

4.  Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.

Authors:  W Paul Farquhar-Smith; Sian I Jaggar; Andrew S C Rice
Journal:  Pain       Date:  2002-05       Impact factor: 6.961

5.  Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.

Authors:  V Di Marzo; D Melck; P Orlando; T Bisogno; O Zagoory; M Bifulco; Z Vogel; L De Petrocellis
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

6.  Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine.

Authors:  Jin Fu; Giuseppe Astarita; Silvana Gaetani; Janet Kim; Benjamin F Cravatt; Ken Mackie; Daniele Piomelli
Journal:  J Biol Chem       Date:  2006-11-22       Impact factor: 5.157

7.  The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.

Authors:  B Romano; F Borrelli; I Fasolino; R Capasso; F Piscitelli; Mg Cascio; Rg Pertwee; D Coppola; L Vassallo; P Orlando; V Di Marzo; Aa Izzo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  The Concise Guide to PHARMACOLOGY 2013/14: ion channels.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; William A Catterall; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands.

Authors:  Adam J Pawson; Joanna L Sharman; Helen E Benson; Elena Faccenda; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Christopher Southan; Michael Spedding; Wenyuan Yu; Anthony J Harmar
Journal:  Nucleic Acids Res       Date:  2013-11-14       Impact factor: 16.971

10.  Novel insights which may translate into treatments for irritable bowel syndrome.

Authors:  Angelo A Izzo
Journal:  Front Pharmacol       Date:  2013-12-31       Impact factor: 5.810

View more
  30 in total

1.  Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.

Authors:  Giorgia Galiazzo; Fiorella Giancola; Agnese Stanzani; Federico Fracassi; Chiara Bernardini; Monica Forni; Marco Pietra; Roberto Chiocchetti
Journal:  Histochem Cell Biol       Date:  2018-06-07       Impact factor: 4.304

Review 2.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

Review 3.  The endocannabinoid system - a target for the treatment of LUTS?

Authors:  Petter Hedlund; Christian Gratzke
Journal:  Nat Rev Urol       Date:  2016-07-05       Impact factor: 14.432

Review 4.  The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.

Authors:  Stefania Petrosino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2016-09-29       Impact factor: 8.739

Review 5.  The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.

Authors:  Alain Veilleux; Vincenzo Di Marzo; Cristoforo Silvestri
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

6.  Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent.

Authors:  Francesca Borrelli; Barbara Romano; Stefania Petrosino; Ester Pagano; Raffaele Capasso; Diana Coppola; Giovanni Battista; Pierangelo Orlando; Vincenzo Di Marzo; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

Review 7.  Endocannabinoids--at the crossroads between the gut microbiota and host metabolism.

Authors:  Patrice D Cani; Hubert Plovier; Matthias Van Hul; Lucie Geurts; Nathalie M Delzenne; Céline Druart; Amandine Everard
Journal:  Nat Rev Endocrinol       Date:  2015-12-18       Impact factor: 43.330

Review 8.  Non-endocannabinoid N-acylethanolamines and 2-monoacylglycerols in the intestine.

Authors:  Harald S Hansen; Vasiliki Vana
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

Review 9.  An update on PPAR activation by cannabinoids.

Authors:  Saoirse Elizabeth O'Sullivan
Journal:  Br J Pharmacol       Date:  2016-05-19       Impact factor: 8.739

Review 10.  The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.

Authors:  C Hasenoehrl; U Taschler; M Storr; R Schicho
Journal:  Neurogastroenterol Motil       Date:  2016-08-26       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.